Pet scans are used to discover the existence of dementia-inducing Amyloid plaque in the brain for regular clinical use. Based on research published in JAMA Neurology, researchers found out that negative and positive outcomes determined the diagnosis of patients with or without dementia.
Researchers enrolled subjects from patients with cognitive impairments to those without dementia. They found traces of amyloid in both disciplines that provided a bridge between approving amyloid PET in the research setting and applying the diagnostic equipment in clinical practice.
The build-up of beta-amyloid in the brain is a significant indicator of the development of dementia and Alzheimer’s disease. Carbon-11-labeled Pittsburgh Compounds B (C-11PIB) and amyloid PET imaging modality have become crucial in neuro-degradation finding.
VUMC scientists have been researching amyloid PET scans in certain patients for years. Recently, they’ve began to avail the modality in clinical practice, and they use amyloid PET in individuals visiting their institution’s memory clinic for daily diagnosis.
VUMC amyloid PET agreement consists of radiotracer florbetaben. It’s indicated for PET imaging for estimating beta-amyloid neuritic plaque density among adult patients with mental impairment assessed for Alzheimer’s disease.
Florbetaben is among the F-8- labeled amyloid PET tracer approved by the US Food and Drug Administration and the European Medicine Agency for medical use. The other two include Florbetapir and flutemetamol.
Amyloid PET has been confirmed to be an accurate, stable method used for visualizing cerebral amyloid plaques. Studies showing the importance of amyloid PET in patients whose diagnosis and treatment depends on amyloid PET status are unavailable.
Patients from VUMC’s memory clinic participated in Alzheimer’s Biomarkers in Daily practice project from January 2015 to December 2016. The mean age of the participants was 65 years of age with different degrees of cognitive issues and dementia.
Researchers discovered that the PET scans of 242 patients had evidence for amyloid. Out of the 164 patients with Alzheimer’s, 128 were amyloid positive. The other most prevalent group comprised of those subjects with non-Alzheimer’s 45 of 70 positives for amyloid. The PET scan results reduced patients’ uncertainty and anxiety.